Showing results (321-330 of 406) with videos related to

Sort By:
Pageof 41
Leukemia|February 18, 2021
Selective elimination of immunosuppressive T cells in patients with multiple myelomaMohamed H S Awwad, Abdelrahman Mahmoud, Heiko Bruns, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 30, 2025
Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent StudiesPhilippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, et al.
International Journal of Molecular Sciences|January 8, 2025
Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot StudyLorenz Oelschläger, Axel Künstner, Friederike Frey, et al.
Blood|January 6, 2023
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myelomaNicola Giesen, Manik Chatterjee, Christof Scheid, et al.
Advances in Therapy|March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple MyelomaPhilippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.
Haematologica|May 20, 2014
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinibBenjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, et al.
Haematologica|December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceMaria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
The Lancet. Oncology|May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G Richardson, Albert Oriol, Meral Beksac, et al.
Future Oncology (London, England)|May 22, 2023
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myelomaThierry Facon, Shaji K Kumar, Torben Plesner, et al.
International Journal of Molecular Sciences|June 27, 2024
Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income CountriesAnja Seckinger, Hans Salwender, Hans Martin, et al.
Pageof 41